Advertisement

De medicamenteuze behandeling van stemstoornissen

juni 2001
  • H.F.M. Peters
  • R. Bastiaanse
  • J. Van Borsel
  • P.H.O. Dejonckere
  • K. Jansonius-Schultheiss
  • Sj. Van der Meulen
  • B.J.E. Mondelaers

Samenvatting

Wanneer een bovenste luchtweginfectie zich uit door keelpijn is er een ontsteking van het slijmvlies van farynx en/of tonsillen en/of het proximale deel van de larynx. Pas wanneer er (ook) stemverandering optreedt, is er sprake van (echte) laryngitis; de ontsteking is dan doorgedrongen tot het niveau van de stemplooien.

Literatuur

  1. Adams, R.A., & Victor, M. (1989). Principles of Neurology (4th ed).[] McGraw–Hill Information Services Company, 54–62; 937–943. ISBN 0–07–100122–0.Google Scholar
  2. Adams, S.G., e.a. (1993). Unilateral versus bilateral botulinum toxin injections in spasmodic dysphonia: acoustic and perceptual results. Journal of Otolaryngology, 22: 171–175.Google Scholar
  3. Adams, S.G. e.a. (1995). Comparison of botulinum toxin injection procedures in adductor spasmodic dysphonia. Journal of Otolaryngology, 24: 345–351.Google Scholar
  4. American Academy of Neurology (1990). Report of the Therapeutics and Technology Assessment Subcommittee. Assessment the clinical usefulness of botulinum toxin–A in treating neurological disorders. Neurology, 40: 1332–1336.Google Scholar
  5. Anonymus (2000). Pariet, protonpompremmer. Geneesmiddelen bulletin, 34: 61.Google Scholar
  6. Aronson, A.E. & DeSanto, L.W. (1983). Adductor spastic dysphonia: three years after recurrent laryngeal nerve resection. Laryngoscope, 93: 1–8.Google Scholar
  7. Berendse, H.W. (2000). Wat is de plaats van dopamine–agonisten bij de behandeling van de ziekte van Parkinson, afzonderlijk en in combinatie? Neurologen vademecum nr. 7/8 (juli/augustus).Google Scholar
  8. Blitzer, A. e.a. (1988). Localized injections of botulinum toxin for the treatment of focal laryngeal dystonia (Spastic Dysphonia). Laryngoscope,98: 193–197.Google Scholar
  9. Blitzer, A., e.a. (1992). Abductor laryngeal dystonia: a series treated with botulinum toxin. Laryngoscope, 102: 163–167.Google Scholar
  10. Blitzer, A., e.a. (1998). Botulinum toxin management of spasmodic dysphonia (Laryngeal Dystonia): a 12–year experience in more than 900 patients. Laryngoscope, 108: 1435–1441.Google Scholar
  11. Blitzer, A, & Brin, M.F. (1992). Treatment of spasmodic dysphonia (Laryngeal Dystonia) with local injections of botulinum toxin. Journal of Voice, 6: 365–369.Google Scholar
  12. Boermeester, M.A., Sandick, J.W., Lanschot, J.J.B. van, Boeckxstaens, G.E., e.a. (1998). Gastro–oesofageale tefluxziekte: pathofysiologie, diagnostiek en medicamenteuze therapie. Ned.Tijdschrift Geneeskunde, 142: 1306–1310.Google Scholar
  13. Bouvy, M. (1994). Farmacotherapie bij ziekte van Parkinson. Geneesmiddelen Bulletin, 28: 44–47.Google Scholar
  14. Bough, I.D., Satalof; R.T., Casteel, D.O., Hills, J.R., Gideon, R.M., & Spiegel, J.R. (1995). Gastroesophageal reflux laryngitis risistant to omeprazole therapy. Journal of Voice., 9: 205–211.Google Scholar
  15. Brin, M.F., e.a. (1989). Adductor laryngeal dystonia (spastic dysphonia): treatment with local injections of botulinum toxin (Botox). Movement Disorders, 4: 287–296.Google Scholar
  16. Brin, M.F., e.a. (1998). Laryngeal dystonia (spasmodic dysphonia): observations of 901 patients and treatment with botulinum toxin. Advances in Neurology 78: 237–252.Google Scholar
  17. Buchholz, D. W., & Neumann, S. (1997). Comments on selected dysphagia litterature. Dysphagia, 12: 57–60.Google Scholar
  18. Capper, M.P., Smit, C.F., Stanojcic, L.D., Devtiese, P.P., e.a. (2000). High incidence of laryngopharyngeal reflux in patients with head and neck cancer. The Laryngoscope, 110: 1007–1011.Google Scholar
  19. Cohen, J.R., Sataloff; R.T., Spiegel, J.R., Fish, J.F., e.a. (1991). Airway reactivity–induced asthma in singers (arias). Journal of Voice, 5, 332–337.Google Scholar
  20. Comella, C.L., e.a. (1992). Dysphagia after botulinum toxin injections for spasmodic torticollis. Neurology, 42: 1307–1310.Google Scholar
  21. Critchy, E.M.R. (1981). Speech disorders of Parkinsonism: a review. Journal of Neurology, Neurosurgery and Psychiatry, 44: 751–758.Google Scholar
  22. Dedo, H.H. (1976). Recurrent laryngeal nerve section for spastic dysphonia. Annals of Otology, Rhinology & Laryngology, 85: 451–459.Google Scholar
  23. Deenstra, M. (1992). De inhalatie als toedieningsvorm van geneesmiddelen. Geneesmiddelen bulletin, 26: 44–47.Google Scholar
  24. Devriese, P.P. (1994). Stemband–dyskinesieën. In: Aspecten van stemstoomissen. Rapport Werkgroep Foniatrie Nederlandse Vereniging voor K.N.O.–Heelkunde en Heelkunde van het Hoofd–Halsgebied, 119–128.Google Scholar
  25. Devriese, P.P., & Speelman, J.D. (1994). Behandeling van stemband–dyskinesieën. Nederlands Tijdschrift voor Geneeskunde, 138: 944–947.Google Scholar
  26. Devriese, P.P. Botuline, een tweesnijdend zwaard. (1998). Geschiedenis der Geneeskunde, 5: 293–299.Google Scholar
  27. Devriese, P.P. (1999). Botulinum toxin in adductor spasmodic dysphonia. Injection technique and results. Proceedings 24th IALP–Congress, Amsterdam 1998. Dejonckere, P.H.O. & Peters, H.F.M. (Eds.). University Press, Nijmegen, 302–304.Google Scholar
  28. Diagnosrisch Kompas 1999–2000. College voor Zorgverzekeringen. Keelpijn, acute, 238–239.Google Scholar
  29. Farmacotherapeutisch Kompas 2000/2001. College voor Zorgverzekeringen: Overige middelen voor astma en copd, 513–515; Mucolytica, oraal, 515–519; Middelen bij hoest en verkoudheid, 484–489; Analgetica, 926–962; Middelen bij infectieziekten, Antibiotica, 697–747; Middelen bij allergische aandoeningen, Antihistaminica, 1064–1073; Glucocorticoïden, 841–850.Google Scholar
  30. Farmacotherapeutisch Kompas 2000/2001. College Voor zorgverzekeringen, Anxiolytica, 69–72; Benzodiazepinen, 72–81; Antidepressiva, 110–132; Bèta–receptorblokkerende sympathicolytica, 282–299.Google Scholar
  31. Farmacotherapeutisch Kompas 2000/2001. College voor zorgverzekeringen. Parkinsonmiddelen, 153–166.Google Scholar
  32. Farmacotherapeutisch Kompas 2000/2001. VI Tracrus Digestivus, 415–439.Google Scholar
  33. Ford, C.N., e.a. (1992). Botulinum toxin treatment of spasmodic dysphonia: techniques, indications, efficacy. Journal of Voice, 6: 370–376.Google Scholar
  34. Fritzell, B., e.a. (1993). Long–term results of recurrent laryngeal nerve resection or adductor spastic dysphonia. Journal of Voice, 7: 172–178.Google Scholar
  35. Gamboa, J., Jiminez–Jeminez, F., Nieto, A., Montojo, J., Orti–Paraja, M., Molina, A., e.a. (1997). Journal of Voice, 3: 314–320.Google Scholar
  36. Gates, G., & Montalbo, Ph.J. (1987). The effect of low–dose ß–blockade on performance anxiety in singers. Journal of Voice, 1: 105–108.Google Scholar
  37. Gates, G.A., Saegert, J., Wilson, N., Johnson, L., Shepherd,A., & Hearne, E.M. (1985). Annals Otol. Rhino. Laryngol., 94: 570–574.Google Scholar
  38. Green, D.C., e.a. (1992). Point–touch technique of botulinum toxin injection for the treatment of spasmodic dysphonia. Annals of Otology, Rhinology & Laryngology, 101: 883–887.Google Scholar
  39. Hacki, T., Kenklies, M., Hofman, R., e.a.. (1990). Pharmakotherapie von Stimm– und Artikulationsstorungen bei Aphasie. Folia Phoniatrica, 42: 283–288.Google Scholar
  40. Hanson, D.G., Garrat, B.R., Ward, P.H., & Los Angelas, C.A. (1984). Cinegraphic observations of laryngeal function in Parkinson's disease. Laryngoscope, 94: 348–353.Google Scholar
  41. Hanson, D.G., Jiang, J.J., Chen, J., e.a. (1997). Acoustic measurement of change in voice quality with treatment for chronic posterior laryngitis. Ann. Otologyl, Rhinology Laryngo1ogy, 106: 279–285.Google Scholar
  42. Hartley, L.R., Ugapen, S., Davie, I., & Spencer, D.J. (1983). The effect of beta–adrenergic blocking drugs on speakers' performance and memory. British Journal Psychiatry, 142: 512–517.Google Scholar
  43. Hollinger, L.E. (1986). Pharmacotherapeutic considerations in anxiety disorders. Journal Clonical Psychiatry, 47 (Suppl. June): 33–36.Google Scholar
  44. Holzer, S.E., & Ludlow, C.L. (1996). The swallowing side effects of botulinum toxin type A injection in spasmodic dysphonia. Laryngoscope, 106: 86–92.Google Scholar
  45. Izdebski, K., e.a. (1981). Postoperative and follow–up studies of spastic dysphonia patients treated with recurrent laryngeal nerve section. Otolaryngol. Head Neck Surgery, 89: 96–101.Google Scholar
  46. Jansen, E.N.H., & Laar, T. van (1990). ‘Oude wijn in nieuwe zakken’; therapie mer subcurane apomorfine bij de ziekre van Parkinson. Ned. Tijdschrift voor Geneeskunde, 134: 889–891.Google Scholar
  47. Jiang, J., Lin, E., Wang, J., e.a. (1999). Glottografic measures before and after Levodopa treatment in Parkinson's disease. The Larynoscope, 109: 1287–1294.Google Scholar
  48. Jong, de P.T.V.M., e.a. (1991). Vijftien jaar therapeutisch toepassen van botuline A toxine. In: J.C. van Es, E. Mandema, G. Olthus, E. Verstraete (red.), Het Medisch Jaar 1991. Houten/Antwerpen: Bohn Stafleu Van Loghum, 274–277.Google Scholar
  49. Klinkenberg–Knol, E.C. (1992). The role of omeprazole in healing and prevention of reflux disease. Hepatogastroenterology, 39 (Suppl 1): 27–30.Google Scholar
  50. Klinkenberg–Knol, E.C., Festen, H.P.M., Jansen, J.B.M., Lamers, C.B.H.W., e.a. (1994). Long–term treatment with omeprazol for refractory reflux esophagitis: efficacy and safety. Anno Intern Med. 121: 161–167.Google Scholar
  51. Kobayashi, T., e.a. (1993). Botulinum toxin treatment for spasmodic dysphonia. Acta Oto–Laryngologica (Suppl. 504): 155–157.Google Scholar
  52. Kompoliti, K., Wang, Q.E., Goetz, C.G., Leurgans, S., & Raman, R. (2000). Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease. Neurology, 54: 458–462.Google Scholar
  53. Koriwchak, M.J., e.a. (1996). Alternating unilateral botulinum toxin type A (BotoX) injections for spasmodic dysphonia. Laryngoscope, 106: 1476–1481.Google Scholar
  54. Koufman, J.A. (1991). The otolaryngologic manifestation of gastroesophageal reflux disease (gerd): a clinical investigation of 225 patients using ambulatoty 24–hours pH monitoring and an experimental investigation of the role of acid and pepsin in the development oflaryngeal injuty. The Laryngoscope, 101 (Supp1 53): 1–78.Google Scholar
  55. Kumazawa, H., Asako, M.,Yamashita, T., e.a. (1997). An increase in laryngeal aerosol deposition by ultrasonic nebulizer therapy with interrnitrend vocalisation. The Larynsoscope, 107: 671–674.Google Scholar
  56. Lader, M. (1988). ß–Adrenoceptor antagonists in neuropsychiatry: An update. Journal Clincal. Psychiatr.,49: 213–223.Google Scholar
  57. Langeveld, T.P. (1998). Unilateral versus bilateral botulinum toxin injections in adductor spasmodic dysphonia. Annals of Otology, Rhinology & Laryngology, 107: 280–284.Google Scholar
  58. Levine, H.L., e.a. (1979). Recurrent laryngeal nerve section for spasmodic dysphonia. Annals of Otology & Laryngology, 88: 527–530.Google Scholar
  59. Liu, T.C., e.a. (1996). Prospective study of patients' subjective responses to botulinum toxin injections for spasmodic dysphonia. Journal of Otolaryngology, 25: 66–74.Google Scholar
  60. Liu, C.Y. (1998). Emotional Symptoms are secundary to the voice disorder in patients with spasmodic dysphonia. General Hospital Psychiatry, 20: 255–259.Google Scholar
  61. Ludlow, C.L., e.a. (1988). Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia. Neurology, 38: 1220–1225.Google Scholar
  62. Ludlow, C.L., e.a. (1992). A comparison of injection techniques using botulinum toxin injection for treatment of the spasmodic dysphonias. Journal of Voice, 6: 380–386.Google Scholar
  63. Lundy, D.S. (1998). The effect of patient factors on response outcomes to Botox treatment of spasmodic dysphonia. Journal of Voice, 12: 460–466.Google Scholar
  64. Miller, R.H., e.a. (1987). Botulinum toxin injection of the vocal cord for spasmodic dysphonia. A preliminary report. Archives of Otolaryngology – Head and Neck Surgery, 113: 603–605.Google Scholar
  65. Murry, T., & Woodson, G.E. (1995). Combined–modality treatment of adductor spasmodic dysphonia with botulinum toxin and voice therapy. Journal of Voice, 9: 460–465.Google Scholar
  66. Perry, P.J., Alexander, B., & Liskow, B.I. (1997). Psychiatric Drug Handbook(7th. ed.)Antianxiety Agents (Anxiolytics)–ß–Blockers, 330–331. ISBN 0–88048–851–4.Google Scholar
  67. Ramig, L.O. & Verdolini, K. (1998). Treatment efficacy: voice disorders. Speech and Hearing Research, 41: 101–116.Google Scholar
  68. Rhew, K., e.a. (1994). Technique for injection of botulinum toxin through the flexible nasolaryngoscope. Otolaryngology – Head & Neck Surgery, 111: 787–794.Google Scholar
  69. Roos, R.A.C., Laar, T. van & Hilren, J.J. van (1994). Beperkte waarde van de apomorfinetest bij de ziekte van Parkinson. Ned. Tijdschrift voor Geneeskunde, 138: 1374–1377.Google Scholar
  70. Schalén, L., Eliasson, I., Kamme, C., e.a. (1993). Erythromycin in acute laryngitis in adults. An. Otol. Rhinol. Laryngologie, 102: 209–214.Google Scholar
  71. Scott, A.B. (1980). Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 87: 1044–1049.Google Scholar
  72. Sellin, C. (1981). The action of botulinum toxin at the neuromuscular junction. Medical Bio1ogy, 59: 11–20.Google Scholar
  73. Shaw, G.Y., & Searl, J.P. (1997). Laryngeal rnanifestation of gastroesophageal reflux before and after treatment with omeprezole. South Med Journal,90: 1115–1122.Google Scholar
  74. Speelman, J.D., e.a. (1996). Neurological indications for botulinum treatment. Proceedings of Biomedical Aspects of Clostridial Neurotoxins. Ranter, H.S. (ed.). Oxford Conference 1996. camr, 85–88.Google Scholar
  75. Tewary, A.K. (1996). Correlation between clinical response and injection quality in treatment of spasmodic dysphonia. Journal of Laryngology & Otology, 110: 551–553.Google Scholar
  76. Tison, F., Wiart, L., Guatterie, M., Fouiller, N., Lozano, V., e.a. (1996). Effect of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease. Moving Disorders, 11: 729–732.Google Scholar
  77. Toogood, J.H. (1990). Complications of topical steroid therapy for asthma. Am. Rev. Respir. Des., 141: 89–96.Google Scholar
  78. Toogood, J.H., Jennings, B., Greenway, R.W., e.a. (1980). Journal Allergy, Clinical Immunology, 65: 145–153.Google Scholar
  79. Truong, D.D, e.a. (1991). Double–blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope, 101: 630–634.Google Scholar
  80. Uijen, J.H.J.M., Ponsioen, B.P., & Jongste, J.C. (1994). Inhalatiemedicatie: toedieningsvormen en hulpmiddelen. Een literatuuronderzoek. Huisarts en Wetenschap, 37: 194–197.Google Scholar
  81. Van Ermengem E. (1897). Ueber einen neuen anaëroben Bacillus und seine Beziehungen zum Botulismus. Zeitschrift für Hygiene und Infektionskrankheiten (Leipzig), 26: 1–56.Google Scholar
  82. Whurr, R., e.a. (1993). The use of botulinum toxin in the treatment of adductor spasmodic dysphonia. Journal of Neurology, Neurosurgery & Psychiatry, 56: 526–530.Google Scholar
  83. Whurr, R., e.a. (1995). Comparison of dosage effects between the American and British botulinum toxin A products in the treatment of spasmodic dysphonia (abstract). Movement Disorders, 10: 387.Google Scholar
  84. Wijngaarden, H.A. van (1977). De invloed van geluid op het neerslaan van ingeademde nevel. Proefschrift. Utrecht: Rijksuniversiteit te Utrecht.Google Scholar
  85. Wijngaarden, H.A. van (1983). De behandeling van acute stemklachten door laryngitis. Logopedie en Foniatrie, 55: 389–393.Google Scholar
  86. Wijngaarden, HA. van, Hoekstra, A., Damsté, P.H., & Fokkens, J.K. (1978). Is it useful to apply aerosol therapy for laryngeal diseases? Niet–gepubliceerd onderzoekverslag.Google Scholar
  87. Williams, A.J., Baghar, M.S., Stableforth, D.E., e.a. (1983). Dysphonia caused by inhalation steroids: recognition of a characretistic laryngeal abnormality. Thorax, 38: 813–821.Google Scholar
  88. Wilson, J.A., White,A., Haacke, N.P. von, Maran, A.G.D., Heading, R.C., Pryde, A., & Pris, J. (1989). Gastroesophageal reflux and posterior laryngitis. Anno Oto. Rhino. Laryngol, 98: 405–410.Google Scholar
  89. Wiltink, E.H.H., e.a. (1992). Botuline: een toxine als therapeuticum. Pharmaceutisch Weekblad, 127: 1037–1041.Google Scholar
  90. Wolters, E.Ch, & Groenewegen, H.J. (1996). Neurologie: Structuur, functie en dysfunctie van het zenuwstelsel. Houten: Bohn Stafleu Van Loghum.Google Scholar
  91. Yin, S.S., e.a. (1997). Major patterns of laryngeal electromyography and their clinical application. Laryngoscope, 107: 126–136.Google Scholar
  92. Yorkston, K.M. (1996). Treatment efficacy: dysarthria. Journal Speech and Hearing Research, 39: S46–57.Google Scholar
  93. Zwirner, P., e.a. (1993). A comparison of bilateral and unilateral botulinum toxin treatments for spasmodic dysphonia. European Archives of Oto–Rhino–Laryngology, 250: 271–276.Google Scholar

Aanbevolen literatuur

  1. Blitzer, A., e.a. (1992). Neurolgic Disorders of the Larynx. NewYork: Thieme.Google Scholar
  2. Brin, M.F., e.a. (1998). Laryngeal dystonia (Spasmodic Dysphonia): Observations of 901 patients and treatment with botulinum toxin. Advances in Neurology, 78: 237–252.Google Scholar

Copyright information

© Bohn Stafleu van Loghum, onderdeel van Springer Media 2014

Authors and Affiliations

  • H.F.M. Peters
  • R. Bastiaanse
  • J. Van Borsel
  • P.H.O. Dejonckere
  • K. Jansonius-Schultheiss
  • Sj. Van der Meulen
  • B.J.E. Mondelaers

There are no affiliations available

Personalised recommendations